WallStSmart

Lifecore Biomedical Inc. (LFCR)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 13274% more annual revenue ($17.32B vs $129.47M). TEVA leads profitability with a 4.1% profit margin vs -23.8%. TEVA appears more attractively valued with a PEG of 0.67. TEVA earns a higher WallStSmart Score of 49/100 (D+).

LFCR

Avoid

30

out of 100

Grade: F

Growth: 4.0Profit: 3.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: -0.50

TEVA

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 5.0Quality: 3.5
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

LFCR0 strengths · Avg: 0/10

No standout strengths identified

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.678/10

Growing faster than its price suggests

Areas to Watch

LFCR4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$164.66M3/10

Smaller company, higher risk/reward

PEG RatioValuation
2.662/10

Expensive relative to growth rate

Return on EquityProfitability
-76.4%2/10

ROE of -76.4% — below average capital efficiency

TEVA4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

P/E RatioValuation
61.3x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : LFCR

LFCR has a balanced fundamental profile.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.67 suggests the stock is reasonably priced for its growth.

Bear Case : LFCR

The primary concerns for LFCR are EPS Growth, Market Cap, PEG Ratio. Debt-to-equity of 9.64 is elevated, increasing financial risk.

Bear Case : TEVA

The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 61.3x leaves little room for execution misses. Debt-to-equity of 2.18 is elevated, increasing financial risk.

Key Dynamics to Monitor

LFCR profiles as a turnaround stock while TEVA is a value play — different risk/reward profiles.

LFCR carries more volatility with a beta of 1.09 — expect wider price swings.

TEVA is growing revenue faster at -0.8% — sustainability is the question.

TEVA generates stronger free cash flow (307M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (49/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Lifecore Biomedical Inc.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Lifecore Biomedical, Inc., is an integrated contract development and manufacturing organization in the United States and internationally. The company is headquartered in Santa Maria, California.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?